Patent ID: 8591903

Claim:
A method of making a pharmaceutical composition for treatment of a disorder which is caused by or associated with a transactivation of receptor tyrosine kinases by G protein or G protein-coupled receptor mediated signal transduction in a cell comprising combining pharmaceutically acceptable carriers, diluents, and/or adjuvants with a therapeutically effective dose of A) antibodies or antigen-binding antibody fragments which contain at least one antigen-binding site that specifically inhibits the activity of amphiregulin and at least one antigen-binding site that specifically inhibits the activity of TACE/ADAM17, or B) a mixture of antibodies or antigen-binding antibody fragments wherein some antibodies or antigen-binding antibody fragments contain at least one antigen-binding site that specifically inhibits the activity of amphiregulin and other antibodies or antigen-binding antibody fragments contain at least one antigen-binding site that specifically inhibits the activity of TACE/ADAM17.